This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

NCT06853223

Status	RECRUITING
Phase	Phase 2
Sponsor	University of California, San Francisco
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (5)

- Male or female e18 years of age at the time of lung transplant waitlisting.
- Listed for a bilateral lung transplantation.
- Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
- PGD risk score \> 50% at the time of donor organ offer
- Planned induction with basiliximab, mycophenolatge, and prednisone and routine maintenance immunosuppression of tacrolimus, mycophenolate and prednisone.

Exclusion (4)

- Recipient scheduled to receive alternate induction regimen that is cell depleting such as anti-thymocyte globulin or alemtuzumab.
- Active chronic pulmonary infection in the recipient that are considered relative contraindications to lung transplantation such as Burkholderia or Mycobacterium abscessus.
- Recipient listed for concurrent heart or other solid organ transplantation.
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Locations (1 total)

University of California, San Francisco, San Francisco, California, United States